"The immunotherapeutic AE37 is designed to work indirectly by stimulating the patient's immune system to recognize and kill cancer cells. An advantage of AE37 is that it potently activates a subclass of immune cells, known at CD4+ T cells, to recognize the tumor-specific HER2 protein. This subclass of T cell has been shown to be critical in generating a robust, long-lasting and effective immune response. AE37 consists of a fragment of the tumor-associated HER2 protein modified by a proprietary platform technology developed by Antigen Express scientists."
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
http://www.prnewswire.com/news-relea...300036824.html
I read about it in this discussion thread here whereAntigen Express, NeuVax and AE37 are mentioned. I really don't understand what the delay is in getting these drugs to market.
http://seekingalpha.com/author/rich-steffens/comments
As it is current vaccines on the CDC schedule aren't 100% effective so who decided to set such a high bar for breast cancer immunotherapy? It seems like market dictates are behind some of this.